The medical equipment industry is undergoing a powerful resurgence, fueled by rapid technological progress and a steadily aging global population. Although the COVID-19 pandemic temporarily slowed market momentum, the sector is now bouncing back with increased innovation and a surge in global exports.
Financing is available for quality hospital, surgical center, or medical manufacturing equipment projects. As direct lenders, we can evaluate any viable project and find a way to finance it. Read More
Tariffs on medical equipment can significantly impact the global market, potentially increasing costs, disrupting supply chains, and impacting access to essential healthcare resources for many. Read More
Modern technologies are reshaping the future of medical equipment, enabling more precise, personalized, and efficient care. From Robotics to Diagnostics Equipment, we are seeing some stunning innovation... Read More
If you’re a bank or private equity firm, we’d like to invite you to send us the projects you cannot fund internally but want to maintain the client relationship.
The global medical equipment market is on a strong upward trajectory. It is expected to grow at a compound annual growth rate (CAGR) of 6.3% from 2024 through 2032, eventually reaching an estimated $886 billion in market size.
Modern technologies are reshaping the future of medical devices, enabling more precise, personalized, and efficient care.
Revolutionizing diagnostics, surgical assistance, and predictive analytics.
Allowing custom implants and patient-specific devices with faster production times.
Enhancing precision in surgeries and rehabilitation treatments.
The wearable medical devices market is forecasted to grow at a CAGR of 25.53% between 2025 and 2030, driven by consumer demand for real-time health tracking.
Smart medical devices connected to cloud systems are projected to grow at a CAGR of 29%, reflecting a surge in demand for remote monitoring and telehealth solutions.
Medical equipment—especially imaging systems, surgical robots, and lab analyzers—all retain their value well and can be resold or repurposed, making it attractive collateral for lenders.
Healthcare is an essential service, meaning demand stays relatively stable even during economic downturns. This lowers the lenders' default risk and increases the likelihood of an approval.
Hospitals, surgical centers, labs, and manufacturers usually have consistent revenue streams from insurance reimbursements, contracts, or Medicare/Medicaid, which gives lenders confidence in repayment and allows them to be more flexible with the lease structure and terms.
A highly regulated and often publicly funded industry, healthcare businesses are perceived as more stable and compliant—another plus for lenders.
Medtronic | United States/Ireland | Cardiovascular, surgical, and diabetes devices |
Johnson & Johnson (DePuy Synthes) | United States | Orthopedic, surgical instruments, wound care |
GE HealthCare | United States | Imaging (MRI, CT, ultrasound), monitoring systems |
Siemens Healthineers | Germany | Imaging systems, diagnostics, lab equipment |
Philips Healthcare | Netherlands | Imaging, monitoring, and respiratory care |
Stryker Corporation | United States | Orthopedic, surgical, neurotechnology |
Baxter International | United States | Renal, infusion therapy, and surgical products |
Boston Scientific | United States | Cardiovascular, endoscopy, neuromodulation |
Fresenius Medical Care | Germany | Dialysis equipment and services |
B. Braun Melsungen AG | Germany | Infusion therapy, surgical instruments, and hospital care |
Terumo Corporation | Japan | Cardiovascular systems, blood management |
Canon Medical Systems | Japan | Diagnostic imaging equipment (CT, MRI, ultrasound) |
Olympus Corporation | Japan | Endoscopy, surgical imaging, ENT equipment |
Smith & Nephew | United Kingdom | Wound management, orthopedics, sports medicine |
Zimmer Biomet | United States | Orthopedic implants, surgical tools |
Mindray Medical | China | Patient monitoring, anesthesia, and imaging |
Shenzhen Mindray Bio-Medical Electronics | China | Diagnostics, imaging, and veterinary equipment |
Drägerwerk AG | Germany | Anesthesia machines, ventilators, neonatal care |
Hitachi Healthcare | Japan | Diagnostic imaging and ultrasound |
BD (Becton, Dickinson & Co.) | United States | Surgical tools, diagnostics, lab, and hospital supplies |
Broad Tariff Increases: The U.S. has implemented a 10% universal tariff on all imported goods, with additional country-specific tariffs of 100 %+ on China, 26% on India, 20% on the European Union, and 25% on Canada and Mexico. More at tariff.bigbenmedical.com
Specific Medical Equipment Affected:
All equipment sources outside the US or those with a portion of their supply chain offshore.
Imagery equipment will be impacted as most large manufacturers are in Europe.
Turning to the used market will also be problematic, as the secondary markets have already significantly increased the value of used equipment.
Other Equipment: Diagnostic tools, blood pressure cuffs, and sterile drapes are also subject to increased tariffs.
Industry Impact: These tariffs affect approximately 75% of U.S.-marketed medical equipment and devices, many manufactured abroad, leading to increased healthcare costs.
Raw Material Tariffs: Tariffs on essential components like aluminum, steel, and semiconductors disrupt the medical equipment supply chain, leading to higher production costs and potential shortages in the medical device and diagnostic industry.
Manufacturer Responses:
Johnson & Johnson: Anticipates $400 million in tariff-related expenses in 2025, primarily affecting its medical technology division.
Abbott Laboratories: Maintains its profit forecast despite global tariff uncertainties, investing $500 million in U.S. manufacturing to mitigate risks.
Increased Operational Costs: Hospitals and clinics face higher prices for essential equipment, straining budgets and potentially leading to increased patient costs.
Potential Shortages: Tariffs may lead to delays or limited access to necessary medical equipment, affecting patient care quality, or scenarios where the right life-saving equipment is not available.
Domestic Production Initiatives: Companies invest in U.S.-based manufacturing to reduce reliance on imported goods and mitigate tariff impacts.
Policy Advocacy: Industry groups call for tax incentives and regulatory support to encourage domestic production and address supply chain vulnerabilities.